| Darci M Komac, OT | |
|
13400 E Shea Blvd, Scottsdale, AZ 85259 | |
| (480) 301-8000 | |
| Not Available |
| Full Name | Darci M Komac |
|---|---|
| Gender | Female |
| Speciality | Occupational Therapist |
| Location | 13400 E Shea Blvd, Scottsdale, Arizona |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1306829148 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225X00000X | Occupational Therapist | 2422 (Arizona) | Primary |
| Provider Name | Mayo Clinic Arizona |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1558332494 PECOS PAC ID: 7012829930 Enrollment ID: O20031105000782 |
News Archive
Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that the U.S. Food and Drug Administration (FDA) has accepted and filed for review Genentech's new drug application (NDA) for vismodegib for the treatment of adults with advanced basal cell carcinoma (BCC) for whom surgery is considered inappropriate.
Study findings suggest that a large number of pediatric hospitalizations, particularly those of a respiratory nature, could be prevented.
Researchers at the Weizmann Institute of Science have shown in mice that intestinal microbes, collectively termed the gut microbiome, may affect the course of amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease.
Pfizer said today it will work with the U.S. Food and Drug Administration (FDA) to add expanded risk information in the Celebrex label following an FDA decision announced this morning to require boxed warnings of potential cardiovascular risk for all COX-2 pain relievers and all NSAIDs, including older non-specific drugs such as ibuprofen and naproxen.
Gilead Sciences, Inc. today announced that it has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for marketing approval for the fixed-dose combination of Truvada® (emtricitabine and tenofovir disoproxil (as fumarate)) and Tibotec Pharmaceuticals' investigational non-nucleoside reverse transcriptase inhibitor TMC278 (rilpivirine (as hydrochloride)) for the treatment of HIV-1 infection in adults.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Darci M Komac, OT 13400 E Shea Blvd, Scottsdale, AZ 85259-5452 Ph: (480) 301-8000 | Darci M Komac, OT 13400 E Shea Blvd, Scottsdale, AZ 85259 Ph: (480) 301-8000 |
News Archive
Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that the U.S. Food and Drug Administration (FDA) has accepted and filed for review Genentech's new drug application (NDA) for vismodegib for the treatment of adults with advanced basal cell carcinoma (BCC) for whom surgery is considered inappropriate.
Study findings suggest that a large number of pediatric hospitalizations, particularly those of a respiratory nature, could be prevented.
Researchers at the Weizmann Institute of Science have shown in mice that intestinal microbes, collectively termed the gut microbiome, may affect the course of amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease.
Pfizer said today it will work with the U.S. Food and Drug Administration (FDA) to add expanded risk information in the Celebrex label following an FDA decision announced this morning to require boxed warnings of potential cardiovascular risk for all COX-2 pain relievers and all NSAIDs, including older non-specific drugs such as ibuprofen and naproxen.
Gilead Sciences, Inc. today announced that it has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for marketing approval for the fixed-dose combination of Truvada® (emtricitabine and tenofovir disoproxil (as fumarate)) and Tibotec Pharmaceuticals' investigational non-nucleoside reverse transcriptase inhibitor TMC278 (rilpivirine (as hydrochloride)) for the treatment of HIV-1 infection in adults.
› Verified 7 days ago
Ms. Attria Batoon Honda, Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 12000 N 90th T., Scottsdale, AZ 85260 Phone: 480-451-2033 | |
Jennifer Klaine, Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 1475 N Granite Reef Rd, Scottsdale, AZ 85257 Phone: 480-990-1904 | |
Jared Stuck, OT Occupational Therapist Medicare: Medicare Enrolled Practice Location: 16413 N 91st St Bldg C145, Scottsdale, AZ 85260 Phone: 480-447-3262 Fax: 480-630-2066 | |
Emily Ludwig, Occupational Therapist Medicare: Medicare Enrolled Practice Location: 13802 N Scottsdale Rd Ste 163, Scottsdale, AZ 85254 Phone: 480-401-1848 | |
Siyu Yi, Occupational Therapist Medicare: Medicare Enrolled Practice Location: 7025 N Scottsdale Rd Ste 200, Scottsdale, AZ 85253 Phone: 602-385-8733 | |
Ms. Connie Sue Williams, OT Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 8115 E Indian Bend Rd, Ste 123, Scottsdale, AZ 85250 Phone: 480-951-6451 | |
Tonya Lee Soules, OT Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 8429 E Via De Jardin, Scottsdale, AZ 85258 Phone: 480-664-1266 |